Related references
Note: Only part of the references are listed.A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Jens Huober et al.
BMC CANCER (2010)
Third consensus on medical treatment of metastatic breast cancer
S. Beslija et al.
ANNALS OF ONCOLOGY (2009)
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
Nilofer S. Azad et al.
CLINICAL CANCER RESEARCH (2009)
Bisphosphonates and Bone Turnover in Premenopausal Women Receiving Adjuvant Chemotherapy
Alexander Paterson
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
Fatima Cardoso et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Manuela Schmidinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
Pegylated liposomal doxorubicin (Caelyx (R)) in metastatic breast cancer: A community-based observation study
Marc Salzberg et al.
ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)
RE Coleman et al.
EUROPEAN JOURNAL OF CANCER (2006)
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment
MS Ewer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas
DR D'Adamo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Release of doxorubicin in sweat:: first step to induce the palmarplantar erythrodysesthesia syndrome?
U Jacobi et al.
ANNALS OF ONCOLOGY (2005)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
MER O'Brien et al.
ANNALS OF ONCOLOGY (2004)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer
AM Keller et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Advantages of liposomal delivery systems for anthracyclines
TM Allen et al.
SEMINARS IN ONCOLOGY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century
M. P. Coleman et al.
ANNALS OF ONCOLOGY (2003)
Survival, quality of life and breast cancer
P Mosconi et al.
ANNALS OF ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
